Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.

Trial Profile

Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2013

At a glance

  • Drugs Rifaximin (Primary) ; Lactulose
  • Indications Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top